In March 2006, six healthy volunteers of a Phase I clinical trial who had received a single infusion of the CD28 superagonistic antibody TGN1412 suffered unpredicted devastating effects that left ...
Dr. Ganesh Suntharalingam is the clinical director of intensive care at Northwick Park Hospital in London. Rachel Gotbaum, the interviewer, is an independent producer based in Boston.
In 2006, a human trial on the leukemia drug theralizumab (TGN1412) resulted in high cytokine levels and organ failure in healthy volunteers, despite preclinical studies finding no evidence of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback